2-Methyl-6-[3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]benzoic Acid | 501362-61-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Methyl-6-[3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]benzoic Acid
• 英文别名: 2-methyl-6-[[3-[[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxymethyl]benzoic acid
• CAS: 501362-61-4
• 化学式: C₂₇H₃₁NO₅
• 分子量: 449.547
• InChiKey: ISBNRLAQTNTMJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  81.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  methyl 2-(cis-3-hydroxycyclohexyloxymethyl)-6-methylbenzoate 、 2-(4-methylphenyl)-4-iodomethyl-5-methyloxazole 在 C27H31NO5 作用下， 以gave the product 70 of molecular weight 449.55 (C27H31NO5), MS(ESI)的产率得到2-Methyl-6-[3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]benzoic Acid
  参考文献：
  名称：

  Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals

  摘要：

  本文介绍了二芳基环烷基衍生物及其生理上可接受的盐和生理功能衍生物。化合物包括公式I中定义的基团及其生理上可接受的盐和制备方法。这些化合物通常具有降脂和/或三酰甘油降低作用，例如，适用于治疗脂质代谢紊乱、2型糖尿病和X综合症等疾病。

  公开号：

  US06884812B2

文献信息

• Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals
  申请人：——

  公开号：US20030144332A1

  公开（公告）日：2003-07-31

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  披萨店的员工们正在忙着准备今晚的外卖订单。
• Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：US07399777B2

  公开（公告）日：2008-07-15

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  本文披露了二芳基环烷基衍生物及其生理上可接受的盐和生理功能衍生物。其中化合物包括公式I中的基团，其定义如下，并且还包括它们的生理上可接受的盐和制备它们的过程。这些化合物通常具有降脂和/或降三酰甘油的特性，例如适用于治疗脂质代谢紊乱、II型糖尿病和X综合征等疾病。
• DIARYLCYCLOALKYLDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS PPAR-AKTIVATOREN
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1425014B1

  公开（公告）日：2006-12-13
• US6884812B2
  申请人：——

  公开号：US6884812B2

  公开（公告）日：2005-04-26
• US7399777B2
  申请人：——

  公开号：US7399777B2

  公开（公告）日：2008-07-15